A TNFR2 3′ flanking region polymorphism in systemic lupus erythematosus

被引:6
作者
Sullivan, KE
Piliero, LM
Goldman, D
Petri, MA
机构
[1] Childrens Hosp Philadelphia, Div Immunol & Infect Dis, Philadelphia, PA 19104 USA
[2] Globalnet Serv Inc, Rockville, MD USA
关键词
tumor necrosis factor receptor; polymorphism; systemic lupus erythematosus;
D O I
10.1038/sj.gene.6363662
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
The role of pro-inflammatory cytokines in systemic lupus erythematosus (SLE) remains somewhat controversial. Several studies have shown increased production of TNF alpha and IL-6 in patients with SLE. increased production of IL-6, TNF alpha, and IL-1 soluble receptors have also been reported. This finding is provocative because the soluble receptors have the capacity to act as antagonists. Several other inflammatory disorders are also associated with increased production of soluble TNF alpha receptors suggesting that this may be a general compensatory mechanism designed to down-regulate inflammation. The recent identification of an SLE disease susceptibility locus near the TNFR2 locus (TNFR p75) suggested the hypothesis that genetically driven differences in soluble TNFR2 production could play a role in the genetic susceptibility to SLE. We therefore characterized the frequency of a genetic polymorphism in the 3' untranslated region of the TNFR2 gene in Caucasoid SLE patients and geographically matched controls. No difference in the gene frequency of the two base-pair polymorphism in SLE patients compared to controls was found, nor was there any association with any particular clinical phenotype.
引用
收藏
页码:225 / 227
页数:3
相关论文
共 33 条
[1]  
ABRAHAM LJ, 1993, CLIN EXP IMMUNOL, V92, P14
[2]   CORRELATION BETWEEN SERUM LEVELS OF SOLUBLE TUMOR-NECROSIS-FACTOR RECEPTOR AND DISEASE-ACTIVITY IN SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
ADERKA, D ;
WYSENBEEK, A ;
ENGELMANN, H ;
COPE, AP ;
BRENNAN, F ;
MOLAD, Y ;
HORNIK, V ;
LEVO, Y ;
MAINI, RN ;
FELDMANN, M ;
WALLACH, D .
ARTHRITIS AND RHEUMATISM, 1993, 36 (08) :1111-1120
[3]  
ALJANADI M, 1993, J RHEUMATOL, V20, P1885
[4]   CYTOKINE PROFILE IN SYSTEMIC LUPUS-ERYTHEMATOSUS, RHEUMATOID-ARTHRITIS, AND OTHER RHEUMATIC DISEASES [J].
ALJANADI, M ;
ALBALLA, S ;
ALDALAAN, A ;
RAZIUDDIN, S .
JOURNAL OF CLINICAL IMMUNOLOGY, 1993, 13 (01) :58-67
[5]  
Alvarado Claudia, 1997, Arthritis and Rheumatism, V40, pS79
[6]   The tumor necrosis factor ligand and receptor families [J].
Bazzoni, F ;
Beutler, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (26) :1717-1725
[7]   Physical mapping and genomic structure of the human TNFR2 gene [J].
Beltinger, CP ;
White, PS ;
Maris, JM ;
Sulman, EP ;
Jensen, SJ ;
LePaslier, D ;
Stallard, BJ ;
Goeddel, DV ;
deSauvage, FJ ;
Brodeur, GM .
GENOMICS, 1996, 35 (01) :94-100
[8]   INCREASED FREQUENCY OF THE UNCOMMON ALLELE OF A TUMOR-NECROSIS-FACTOR-ALPHA GENE POLYMORPHISM IN RHEUMATOID-ARTHRITIS AND SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
DANIS, VA ;
MILLINGTON, M ;
HYLAND, V ;
LAWFORD, R ;
HUANG, QR ;
GRENNAN, D .
DISEASE MARKERS, 1995, 12 (02) :127-133
[9]  
Eskdale J, 1997, ARTHRITIS RHEUM, V40, P283
[10]  
Gabay C, 1997, J RHEUMATOL, V24, P303